A RANDOMIZED CONTROLLED TRIAL OF PANRETINAL PHOTOCOAGULATION WITH AND WITHOUT INTRAVITREAL RANIBIZUMAB IN TREATMENT-NAIVE EYES WITH NON–HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY

Retina ◽  
2015 ◽  
Vol 35 (2) ◽  
pp. 280-287 ◽  
Author(s):  
Daniel A. Ferraz ◽  
Lisa M. Vasquez ◽  
Rony C. Preti ◽  
Augusto Motta ◽  
Raafay Sophie ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Controlled Trial ◽  
Panretinal Photocoagulation ◽  
Intravitreal Ranibizumab ◽  
Randomized Controlled ◽  
Treatment Naïve

Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial

2015 ◽  
Vol 235 (1) ◽  
pp. 34-41 ◽  
Author(s):  
João Figueira ◽  
Rufino Silva ◽  
José Henriques ◽  
Paulo Caldeira Rosa ◽  
Inês Laíns ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Controlled Trial ◽  
Combined Treatment ◽  
Panretinal Photocoagulation ◽  
Complete Regression ◽  
Duration Of Treatment ◽  
Intravitreal Ranibizumab ◽  
Rescue Treatment

Purpose: To compare the efficacy and safety of intravitreal ranibizumab (IVR) in monotherapy or associated with panretinal photocoagulation (PRP) versus conventional PRP, for high-risk proliferative diabetic retinopathy (PDR) without vitreoretinal traction. Procedures: Multicenter randomized trial, with 3 treatment arms: PRP versus IVR alone and PRP + IVR combined treatment. Follow-up was performed at months 3, 6 and 12. Results: Thirty-five subjects were randomized and 32 used for analysis. Complete regression of neovessels elsewhere occurred in 100% (PRP + IVR), 75% (IVR) and 69.2% (PRP) and for neovessels of the disk in 44.4% (PRP + IVR), 37.5% (IVR) and 30.8% (PRP). During the 1-year duration of treatment, there was no need for laser rescue treatment in IVR-treated eyes. Conclusions: This trial suggests that the use of IVR is safe and may have a beneficial effect in the treatment of eyes with high-risk PDR. Message: Ranibizumab appears to have a place in the treatment of PDR.

scholarly journals Single-Session Low Duration Panretinal Photocoagulation Using Conventional Laser on Central Subfield Macular Thickness in Diabetic Retinopathy

2018 ◽  
Vol 12 (1) ◽  
pp. 308-313
Author(s):  
Arief S Kartasasmita ◽  
Prettyla Yollamanda ◽  
Grimaldi Ihsan ◽  
Rova Virgana
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Controlled Trial ◽  
Macular Thickness ◽  
Panretinal Photocoagulation ◽  
Single Session ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Conventional Laser

Objective:To compare the change in central subfield macular thickness following single-session and multiple-session laser panretinal photocoagulation in subjects with diabetic retinopathy.Methods:A single-center, randomized controlled trial study was performed on 28 eyes of 16 patients with severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy. Eyes were randomly assigned for treatment with panretinal photocoagulation performed either in single-session or multiple-session divided into three sessions during two-week period. Central subfield macular thickness was quantified using spectral domain optical coherence tomography and changes at four weeks follow-up were compared to the baseline measurement.Result:Mean baseline central subfield macular thickness of 12 eyes underwent single-session and 16 eyes underwent multiple-session panretinal photocoagulation were 342.91+109.51 micrometers and 354+171.79 micrometers (p> .05), respectively. Mean post laser central subfield macular thickness in the single-session group was 305.83+81.95 micrometers and 389.75+229.51 micrometers in the multiple-session group (p> .05). Mean central subfield macular thickness changes four weeks post laser was 37.08+94.21 micrometers for eyes treated with single-session and -35.75+123.62 micrometers for the multiple-session treated eyes (p= .101).Conclusion:There was no significant difference in change of central subfield macular thickness at four weeks post laser from treatment with single-session and multiple-session panretinal photocoagulation. Single-session panretinal photocoagulation can be used as effective multiple-session panretinal photocoagulation for the treatment of diabetic retinopathy.

Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation

2018 ◽  
Vol 30 (1) ◽  
pp. 34-39
Author(s):  
Guofan Cao ◽  
Xiangzhong Xu ◽  
Chenghu Wang ◽  
Shu Zhang
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Additional Treatment ◽  
Macular Thickness ◽  
Panretinal Photocoagulation ◽  
Central Macular Thickness ◽  
Fundus Fluorescein Angiography ◽  
Intravitreal Ranibizumab ◽  
The Status

Purpose: To compare the outcome of the sequence in the two treatments (intravitreal ranibizumab and panretinal photocoagulation) in high-risk proliferative diabetic retinopathy. Methods: This retrospective study included 35 patients with newly diagnosed high-risk proliferative diabetic retinopathy in 43 eyes; 18 (22 eyes) received intravitreal ranibizumab before panretinal photocoagulation (intravitreal ranibizumab+ group), while the other 17 (21 eyes) received panretinal photocoagulation before intravitreal ranibizumab (panretinal photocoagulation+ group). Each subject received three intravitreal ranibizumabs that were interleaved with three panretinal photocoagulations. The first treatment (either intravitreal ranibizumab or panretinal photocoagulation) was done 1 week before the second one. The interval between intravitreal ranibizumabs was 4 weeks, panretinal photocoagulation was 2 weeks. The power and pulse duration were determined based upon the status of each retinal spot before each panretinal photocoagulation. The retinal non-perfusion region was measured with fundus fluorescein angiography before and 1 month after the final treatment. The central macular thickness was measured with optical coherence tomography within 1 week before the first treatment, before each panretinal photocoagulation, and 1 month after the final intravitreal ranibizumab. Results: The panretinal photocoagulation energy required for effective treatment was lower in intravitreal ranibizumab+ group in the first and second sessions and in total energy (p < 0.05). Central macular thickness reduction before the second panretinal photocoagulation session was significant in the intravitreal ranibizumab+ group (p < 0.05). Conclusion: The sequence used in intravitreal ranibizumab+ group showed clear advantages over that in panretinal photocoagulation+ group in the treatment of proliferative diabetic retinopathy, not only in the use of lower energy for panretinal photocoagulation but also in the more rapid regression of neovascularization and less need of additional treatment.

Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy

2011 ◽  
Vol 89 (7) ◽  
pp. e567-e572 ◽  
Author(s):  
José A. R. Filho ◽  
André Messias ◽  
Felipe P. P. Almeida ◽  
Jefferson A. S. Ribeiro ◽  
Rogério A. Costa ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Panretinal Photocoagulation ◽  
Intravitreal Ranibizumab
Sign in / Sign up

Export Citation Format

Share Document